VANCOUVER, Sept. 09, 2020 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT) an emerging biotech company, today announced that Company CEO Dr. Ahmad Doroudian was interviewed by the Canadian Stock Exchange (CSE) to discuss Betterlife’s post-merger business model and significant changes by management to position the Company for the future.
The CSE’s Barrington Miller and Dr. Doroudian discussed BetterLife’s ambitions and plans post-merger to advance the Company’s clinical trial programs and therapeutic pipeline consisting of three products, including AP-003, a patent-pending interferon a2b (IFNa2b) inhalation formulation. Recent studies from the UK and China have provided compelling data that suggest the therapeutic efficacy of interferon-based treatments for COVID-19.Highlights of the interview include:What BetterLife is doing about COVID-19;How early AP-003 might be available, and how it might also be used for prevention;The differentiators between BetterLife and other companies developing COVID-19 treatments;Why the treatment approach (in addition to a vaccine) is essential in tackling COVID-19; andUpcoming clinical trials to test AP-003 in Australia and what that means for the Company’s investors.The broadcast of the exclusive podcast produced by the CSE can be heard here.About BetterLife Pharma Inc.:BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of therapeutic pharmaceuticals as well as drug delivery platform technologies. BetterLife is refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight virus infections, such as the coronavirus disease (COVID-19) and human papillomavirus (HPV), and/or to directly inhibit tumours to treat specific types of cancer.For further information please visit www.blifetherapeutics.com.           Cautionary NoteThe Company is not making any express or implied claims that  AP-003 or any other product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.ContactDost Mustaq,  BDA International Investor Relations Contact
Email: [email protected]
Phone: 646-679-4321Cautionary Note Regarding Forward-Looking StatementsExcept for historical information, the matters set forth above may be forward-looking statements that involve risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors. Reliance should not be placed on forward-looking statements, as they involve known and unknown risks, uncertainties and other factors that may cause the actual results to differ materially from the anticipated future results expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those set forward in the forward-looking statements include, but are not limited to: our ability to obtain, on satisfactory terms or at all, the capital required for research, product development, operations and marketing; general economic, business and market conditions; our ability to successfully and timely complete clinical studies;  product development delays and other uncertainties related to new product development; our ability to attract and retain business partners and key personnel; the risk of our inability to profitably commercialize our proposed products; the risk that our proposed clinical trials will not be launched in a timely manner (or at all) or if launched yield positive results or that we will not obtain regulatory market approvals for our products;  the extent of any future losses; the risk of our inability to establish or manage manufacturing, development or marketing collaborations; the risk of delay of, or failure to obtain, necessary regulatory approvals and, ultimately, product launches; dependence on third parties for successful commercialization of our products; inability to obtain product and raw materials in sufficient quantity or at standards acceptable to health regulatory authorities to commence and complete clinical trials or to meet commercial demand; our ability to obtain patent protection and protect our intellectual property rights; commercialization limitations imposed by intellectual property rights owned or controlled by third parties; uncertainty related to intellectual property liability rights and liability claims asserted against us; the impact of competitive products and pricing; and  future levels of government funding; additional risks and uncertainties, many of which are beyond our control.Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Bay Street News